Clinical trial
A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults
NCT00034359 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2002
- Completion date
- January 31, 2003
- Enrollment
- 79 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.